case_images: PMC9638685_01
case_images: Skin lesion on the scalp at diagnosis.
case_images: 10.1177_23247096221127114-fig1.jpg
case_images: PMC9638685_01_10.1177_23247096221127114-fig1.jpg
case_images: fig1-23247096221127114
case_images: The skin lesion on the patient's scalp is shown in Figure 1.
case_images: Bone marrow aspirate prior to treatment with vyxeos. (A) Clot aspirate
  section at 20x. (B) Clot aspirate at 10x. (C) and (D) Bone marrow aspirate
  demonstrating blasts.
case_images: 10.1177_23247096221127114-fig2.jpg
case_images: PMC9638685_01_10.1177_23247096221127114-fig2.jpg
case_images: fig2-23247096221127114
case_images: The bone marrow aspirate at relapse is shown in Figure 2.
case_images: Circulating blast in peripheral smear.
case_images: 10.1177_23247096221127114-fig3.jpg
case_images: PMC9638685_01_10.1177_23247096221127114-fig3.jpg
case_images: fig3-23247096221127114
case_images: Figure 3 shows a circulating blast on the peripheral smear.
case_images: Flow cytometry demonstrating the immunophenotype at relapse.
case_images: 10.1177_23247096221127114-fig4.jpg
case_images: PMC9638685_01_10.1177_23247096221127114-fig4.jpg
case_images: fig4-23247096221127114
case_images: The immunophenotype at relapse is shown in Figure 4.
case_images: Bone marrow aspirate a month after vyxeos showing hypocellular marrow at
  10x.
case_images: 10.1177_23247096221127114-fig5.jpg
case_images: PMC9638685_01_10.1177_23247096221127114-fig5.jpg
case_images: fig5-23247096221127114
case_images: Figure 5 demonstrates the bone marrow aspirate done a month after vyxeos. His bone marrow showed a complete response to vyxeos with no evidence of BPDCN (Figure 5).